FISEVIER

Contents lists available at ScienceDirect

Indian Heart Journal

journal homepage: www.elsevier.com/locate/ihj



Short Communication

Thiamine mediated reversal of left ventricular dysfunction in patients with alcoholic cardiomyopathy



Oruganti Sai Satish*, Shabbir Ali Shaik

Department of Cardiology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, 500082, Telangana, India

ARTICLE INFO

Article history:
Received 8 October 2020
Received in revised form
20 March 2021
Accepted 31 March 2021
Available online 2 April 2021

Keywords:
Alcoholic cardiomyopathy(ACM)
Heart failure(HF)
Left ventricular end diastolic
diameter(LVEDD)
Left ventricular end systolic
diameter(LVESD)
Thiamine deficiency(TD)

ABSTRACT

This study aimed to evaluate the effect of thiamine supplementation on left ventricular (LV) systolic function in patients of alcoholic cardiomyopathy(ACM) presenting with acute heart failure(HF). 11 newly diagnosed patients were included. They were treated with 3 days of intravenous(IV) therapy with thiamine followed by oral supplementation. LVEF was 30% at baseline which improved by 45% and 53% along with reduction in LV dimensions over 3 and 6 months respectively. The study suggests the benefit of thiamine supplementation on LVEF in ACM patients with HF.

© 2021 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Alcoholic cardiomyopathy (ACM) is a chronic dilated heart disease with decreased left ventricular ejection fraction(LVEF). Studies have shown thiamine deficiency in patients of acute heart failure.^{1,2} We evaluated the changes in LVEF with thiamine supplementation in patients of ACM presenting with acute heart failure (HF).

2. Aims & objectives

To study the efficacy of thiamine supplementation along with standard medical therapy in ACM patients and reversibility of left ventricular systolic dysfunction.

3. Methods

3.1. Inclusion criteria

Patients presented with acute heart failure of New York Heart Association (NYHA) functional class 3 or 4 with a history of chronic heavy drinking of alcohol were included in the study.

* Corresponding author.

E-mail address: osaisatish@yahoo.com (O.S. Satish).

3.2. Exclusion criteria

- 1. Ischemic cardiomyopathy
- 2. Left ventricular ejection fraction (LVEF) > 45%
- 3. Recent thiamine or multivitamin supplementation

Patients with a first episode of acute heart failure with history of chronic heavy drinking of alcohol i.e, more than 5 years of duration with greater than 80 mg/day were included. Relevant history, electrocardiogram and chest radiograph were taken. Coronary angiogram was performed to rule out ischemic cardiomyopathy. A two dimensional echocardiographic examination was done before starting the treatment with thiamine. After completion of 3 days of intravenous treatment, all patients were given oral thiamine 200 mg/day for a maximum duration of 12 weeks. Patients were evaluated by serial echocardiography.

4. Results

A total of eleven patients were studied. The baseline characteristics are shown in Tables 1 and 2. The average amount of alcohol consumed per day was 60–110 g/day over a mean duration of 14 years. Echocardiographic parameters were studied from admission to 6 months at regular intervals (Table 3). The mean LVEF was 30%

Table 1Baseline characteristics of the study population.

Baseline characteristics	$Total\ (n=11,male)$
Breathlessness	11(100%)
Orthopnea	7(63.6%)
Paroxysmal nocturnal dyspnea	10(90.9%)
Jaundice	3(27%)
Pedal edema	3(27%)
Oliguria	4(36.4%)
Age in years(mean)	44.2 ± 9.2
Alcohol consumed(g/day)	86.82 ± 10.78
Alcohol consumption duration (yrs)	14.1 ± 7.57
H/O Hypertension	6(54.5%)
H/O Diabetes	2(18%)
ECG: LVH with strain	6(54.5%)
Left atrial enlargement	7(63.6%)
Right atrial enlargement	3(27%)

Table 2Mean values of laboratory parameters among study population.

Laboratory parameters	$Total\ (n=11)$		
Hemoglobin(g/100 ml)	14 ± 1.77		
Total leucocyte count(ml)	9363 ± 250		
Platelet count(ml)	5 2×10±0.45		
Total Bilirubin(mg/100 ml)	1.4 ± 0.9		
SGOT(units/L)	100 ± 19		
SGPT(units/L)	80 ± 16		
ALP(units/L)	84 ± 18		
Blood Urea(mg/100 ml)	40 ± 1313		
Serum creatinine (mg/100 ml)	1 ± 0.15		
CPK(units/L)	124 ± 7.6		
LDH(units/L)	208 ± 18		

at baseline improved to 46% at 6 months follow-up (Fig. 1). At admission LVEDD/LVESD were 5.98 ± 0.32 cm/ 4.77 ± 0.62 cm which improved to 5.4 ± 0.33 cm/4,2 ± 0.56 cm at 6 months(Fig. 2). Mitral regurgitation was moderate(2+) in severity at admission which improved to mild(1+) at 6 months. Left atrial size was 3.98 ± 0.49 cm which improved to 3.5 ± 0.3 cm. There was progressive improvement in right ventricular function as assessed by tricuspid annular plane systolic excursion(TAPSE) which was 1.7 ± 0.19 cm at admission to 2 ± 0.1 cm at 6 months and fall in pulmonary artery systolic pressures was 42 ± 8.8mmhg at admission to 31 \pm 8.4mmhg at 4 weeks(Table 3). LVEF improved above 40% in 4(36%) at 14 days and in 7(64%) at 1 month and in all 11 patients (100%) by 3 months (Fig. 3) of thiamine supplementation. There was a 23% increase in LVEF at 14 days from that of baseline value and 45%, 53% increase was noted at 3 and 6 months respectively (Fig. 4).

5. Discussion

Alcohol consumption 80 g/day for at least 5 years significantly increases the risk to develop ACM.³ The "total lifetime dose of ethanol" (TLDE) — the amount of ethanol consumed during lifetime expressed in kilograms per kilograms of body weight (kg/kg) correlates with left ventricle dysfunction, detectable in one third of chronic alcohol consumers.³ Alcohol consumption leads to thiamine deficiency by decreasing the transport of thiamine across the intestinal mucosa, impairing capacity of the liver to store thiamine and impairing the phosphorylation of thiamine to the more

Table 3 Echocardiographic parameters in the study population.

Echocardiogra-phic Parameter	At admission	At Discharge (1 week)	At 14 days	At 1 Month	At 3 Months	At 6 Months
LVEDD(cm)	5.98 ± 0.32	5.8 ± 0.34	5.74 ± 0.22	5.66 ± 0.25	5.5 ± 0.3	5.4 ± 0.33
LVESD(cm)	4.77 ± 0.62	4.75 ± 0.51	4.57 ± 0.69	4.4 ± 0.42	4.2 ± 0.55	4.2 ± 0.56
LVEF(%)	30 ± 4	33 ± 3.2	37 ± 2.77	41 ± 4.9	44 ± 5.2	46 ± 5.7
MR(grade)	2+	2+	1+	1+	1+	1+
LA(cm)	3.98 ± 0.49	3.9 ± 0.42	3.98 ± 0.4	3.64 ± 0.38	3.53 ± 0.34	3.5 ± 0.3
AORTA(cm)	2.72 ± 0.4	2.7 ± 0.34	2.6 ± 0.52	2.74 ± 0.31	2.8 ± 0.31	2.8 ± 0.3
RVSP(mmHg)	42 ± 8.8	39 ± 9.5	36 ± 9.6	33.6 ± 9.74	32.2 ± 9.15	31.6 ± 8.4
TAPSE(cm)	1.7 ± 0.19	1.8 ± 0.13	1.9 ± 0.14	2 ± 0.13	2 ± 0.1	2 ± 0.05




Fig. 1. Graph showing trends in the improvement of LVEF(%) with thiamine supplementation.




Fig. 2. Graph showing trends in the change in LV enddiastolic diameter(LVEDD) (cm) and LV endsystolic diameter(LVESD) (cm) on thiamine treatment.




Fig. 3. Bar diagram showing percentage of patients showing improvement in. LVEF(>40%) on thiamine supplementation.

biological active thiamine diphosphate. Standardisation difficulties, pre-analytical sample preparation (requirement for washed red cells which are not widely available in most biobanks) and sample stability concerns making difficult to assess thiamine levels in patients with suspected thiamine deficiency(TD). TD in HF patients has been observed by Hanninen et al,⁴ Seligmann et al.,⁵ In our study with thiamine addition there was improvement in LVEF in all patients from 30% (baseline) to 44%, 46% at 3 and 6 months respectively.




Fig. 4. $_{\text{Bar}}$ $_{\text{diag}}$ ram showing percentage of increase in LVEF after thiamine supplementation.

6. Limitations

- 1. Small sample size
- 2. Estimation of levels of serum thiamine was not done

7. Conclusion

This study suggests the role of thiamine supplementation along with standard medical therapy in improvement of LVEF in ACM patients with acute HF. However, to validate these findings, a placebo controlled study with a larger number of patients may be desirable.

Declaration of competing interest

NIL.

References

- 1. Leslie D, Gheorghiade M. Is there a role for thiamine supplementation in the management of heart failure? *Am Heart J.* 1996;131:1248–1250.
- Piano MR. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest. 2002;121:1638–1650.
- Fernández-Solà J, Nicolás JM, Paré JC, et al. Diastolic function impairment in alcoholics. Alcohol Clin Exp Res. 2000;24:1830–1835.
- Hanninen SA, Darling PB, Sole MJ, Barr A, Keith ME. The prevalence of thiamine deficiency in hospitalized patients with congestive heart failure. J Am Coll Cardiol. 2006;47:354–361.
- 5. Seligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. *Am J Med.* 1991;91:151–155.